ReachRxResearch
Home
Research
Sign Up
Study limitation
Back to Research Hub
  1. Home
  2. Research Hub
  3. Study limitation

Short‐Course Subcutaneous Immunotherapy With Mannan‐Conjugated Birch Pollen Allergoids: Consistent Clinical and Immunological Improvements

Study limitation reported by the research below: “The primary CSMS effect size (0.31) was below the proposed minimally clinically important difference threshold of 0.5; clinical significance of the benefit should be interpreted cautiously.”

Papers